Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
$20.89
-0.7%
$20.97
$17.45
$70.07
$799.39M0.19894,287 shs1.60 million shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$2.47
+3.8%
$2.15
$1.67
$10.03
$629.01M0.252.29 million shs6.24 million shs
Select Medical Holdings Corporation stock logo
SEM
Select Medical
$15.27
+1.7%
$15.39
$14.03
$40.98
$1.96B1.34980,140 shs3.25 million shs
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$34.74
-4.0%
$33.46
$16.01
$44.34
$3.83B0.96909,379 shs759,523 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
-0.68%-4.76%-0.94%-11.28%-61.00%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
+3.78%+19.90%+11.76%+4.66%-64.41%
Select Medical Holdings Corporation stock logo
SEM
Select Medical
+1.68%+2.97%+3.99%-9.20%-54.92%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-4.01%+0.55%+14.73%-6.84%+93.32%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
4.0846 of 5 stars
3.11.00.04.32.01.71.9
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
3.5787 of 5 stars
3.12.00.04.41.40.80.6
Select Medical Holdings Corporation stock logo
SEM
Select Medical
5 of 5 stars
3.45.02.54.82.94.25.0
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
3.337 of 5 stars
3.45.00.00.03.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
2.25
Hold$32.0853.57% Upside
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.25
Hold$6.64168.78% Upside
Select Medical Holdings Corporation stock logo
SEM
Select Medical
2.80
Moderate Buy$26.0070.32% Upside
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
2.75
Moderate Buy$47.3736.35% Upside

Current Analyst Ratings Breakdown

Latest AMN, ZLAB, MRVI, and SEM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$30.00 ➝ $25.50
5/13/2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
5/13/2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.00
5/7/2025
Select Medical Holdings Corporation stock logo
SEM
Select Medical
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$23.00 ➝ $19.00
4/16/2025
Select Medical Holdings Corporation stock logo
SEM
Select Medical
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$25.00
4/15/2025
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $25.00
(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
$2.98B0.27$13.74 per share1.52$18.56 per share1.13
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$259.18M2.43$0.62 per share4.00$2.28 per share1.08
Select Medical Holdings Corporation stock logo
SEM
Select Medical
$5.19B0.38$2.50 per share6.10$15.35 per share0.99
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$398.99M9.61N/AN/A$7.68 per share4.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
-$146.98M-$4.33N/A8.63N/A-5.80%13.39%4.17%8/6/2025 (Estimated)
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$144.85M-$1.14N/AN/AN/A-67.14%-12.91%-6.87%8/6/2025 (Estimated)
Select Medical Holdings Corporation stock logo
SEM
Select Medical
$214.04M$1.3411.3910.830.812.81%11.04%3.25%7/30/2025 (Estimated)
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$257.10M-$2.49N/AN/AN/A-60.26%-33.35%-23.28%8/5/2025 (Estimated)

Latest AMN, ZLAB, MRVI, and SEM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$0.07-$0.08-$0.01-$0.21$44.01 million$46.85 million
5/8/2025Q1 2025
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
$0.19$0.45+$0.26-$0.03$670.08 million$689.53 million
5/8/2025Q1 2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million
5/1/2025Q1 2025
Select Medical Holdings Corporation stock logo
SEM
Select Medical
$0.45$0.44-$0.01$0.44$1.40 billion$1.35 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
N/AN/AN/AN/AN/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
N/AN/AN/AN/AN/A
Select Medical Holdings Corporation stock logo
SEM
Select Medical
$0.251.64%N/A18.66%N/A
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/AN/AN/AN/AN/A

Latest AMN, ZLAB, MRVI, and SEM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/1/2025
Select Medical Holdings Corporation stock logo
SEM
Select Medical
quarterly$0.06251.37%5/15/20255/15/20255/29/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
1.39
1.08
1.08
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
0.60
5.96
5.17
Select Medical Holdings Corporation stock logo
SEM
Select Medical
0.87
1.16
1.16
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/A
3.26
3.09

Institutional Ownership

CompanyInstitutional Ownership
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
99.23%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
50.25%
Select Medical Holdings Corporation stock logo
SEM
Select Medical
89.48%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
41.65%

Insider Ownership

CompanyInsider Ownership
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
0.93%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.11%
Select Medical Holdings Corporation stock logo
SEM
Select Medical
11.60%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
4.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
AMN Healthcare Services Inc stock logo
AMN
AMN Healthcare Services
2,96838.28 million37.93 millionOptionable
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
610254.66 million249.29 millionOptionable
Select Medical Holdings Corporation stock logo
SEM
Select Medical
44,100128.54 million113.63 millionOptionable
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
1,869110.33 million104.86 millionOptionable

Recent News About These Companies

Zai Lab (NASDAQ:ZLAB) Stock Rating Lowered by Wall Street Zen
Zai Lab Limited (ZLAB) - Yahoo Finance
Cantor Fitzgerald Expects Reduced Earnings for Zai Lab
Analysts Offer Predictions for Zai Lab FY2025 Earnings
Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?
Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's Why
Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Time to Buy?
Cantor Fitzgerald Forecasts Zai Lab FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMN Healthcare Services stock logo

AMN Healthcare Services NYSE:AMN

$20.89 -0.15 (-0.71%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$20.88 -0.02 (-0.08%)
As of 06/27/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

Maravai LifeSciences stock logo

Maravai LifeSciences NASDAQ:MRVI

$2.47 +0.09 (+3.78%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$2.44 -0.03 (-1.01%)
As of 06/27/2025 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Select Medical stock logo

Select Medical NYSE:SEM

$15.26 +0.26 (+1.70%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$15.26 0.00 (0.00%)
As of 06/27/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Select Medical Holdings Corporation, through its subsidiaries, operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. It operates in four segments: Critical Illness Recovery Hospital, Rehabilitation Hospital, Outpatient Rehabilitation, and Concentra. The Critical Illness Recovery Hospital segment consists of hospitals that provide services for heart failure, infectious disease, respiratory failure and pulmonary disease, surgery requiring prolonged recovery, renal disease, neurological events, and trauma. The Rehabilitation Hospital segment offers therapy and rehabilitation treatments, including rehabilitative services for brain and spinal cord injuries, strokes, amputations, neurological disorders, orthopedic conditions, pediatric congenital or acquired disabilities, and cancer. The Outpatient Rehabilitation segment operates rehabilitation clinics that provide physical, occupational, and speech rehabilitation programs and services; and specialized programs, such as functional programs for work related injuries, hand therapy, post-concussion rehabilitation, pediatric and cancer rehabilitation, and athletic training services. The Concentra segment operates and provides occupational health centers, telemedicine platforms, onsite clinics, and contract services at employer worksites that deliver occupational health services, consumer health, physical therapy, and preventive care. Select Medical Holdings Corporation was founded in 1996 and is headquartered in Mechanicsburg, Pennsylvania.

Zai Lab stock logo

Zai Lab NASDAQ:ZLAB

$34.74 -1.45 (-4.01%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$34.73 -0.01 (-0.03%)
As of 06/27/2025 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.